Gibson Dunn Advises Avere Therapeutics on Reverse Merger with NextCure, and Concurrent Private Financing

Firm News  |  July 20, 2026

---

Gibson Dunn is advising Avere Therapeutics, Inc. on its reverse merger transaction with NextCure, Inc. (NASDAQ: NXTC) and concurrent $320 million private financing of shares of common stock and pre-funded warrants to a syndicate of healthcare investors. Upon completion of the transaction, the combined company plans to operate under the name Avere Therapeutics, Inc. and trade on Nasdaq under a new ticker symbol.

The Gibson Dunn corporate team is led by partners Ryan Murr and Branden Berns and includes of counsel Evan Shepherd.